教育行业的我们的系列研究首先是为什么最近我们一直持续还是在强烈的去看好教育赛道首先给大家做一个简单的汇报从去年以来其实我们在A股相继去撰写 学大的深度的这个系列报告然后在港国就是持续撰写这个呃天地的这个相关的这个报告包括也做了很多交流哈就是说人家我们是非常看好目前第一个是消费行业 呃现在目前具有确定性增长而且现在有比较比较的我觉得优良的这样的这个性质在的是教育板块然后其实在目前来说的话如果说就赛道屏住来说的话我觉得在整个消费行业里面可能有很只有很少的或者说很难有出现类似于说像教育板块这样的这样的就说呃 消费力和消费意愿 教育行业来说的话我们觉得不管是属于消费意愿还是说居民实际上的消费力在这一块的一个留存的话我觉得都还是属于自由刚性的所以我们对于教育行业从去年以来的话持续就是开始进行一个精选客户的推荐那整体的效果应该说还是相对是不错的那教育行业我最我个人觉得就是说第一个它是属于民生的这么一个一个行业其实整体来看的话整个家庭不管说大家担心之前的 什么这个结婚的人口越来越少然后少子化的这么一个倾向但是其实从从这个2011年的这个单独二胎到2016年的全面二胎之后其实整个人口红利在如果说是在这个教育行业的话我觉得还是 ...

Summary of HTSC Conference Call Company Overview - **Company**: HTSC (Haitong Securities Company) - **Ticker**: 6886.HK (H-shares), 601688.SS (A-shares) - **Industry**: Financial Services, specifically Brokerage and Asset Management Key Points Financial Performance and Projections - **Asset Sale Impact**: HTSC closed the sale of its US subsidiary, AssetMark, for US$1.79 billion, generating US$795 million in investment gains expected to be booked in Q3 2024, which will support 2024 earnings despite a year-over-year drop in investment income due to weaker equity market performance and regulatory tightening [2][4][16] - **Revenue Forecasts**: - 2024 earnings forecast raised by 28.5% due to the sale-related gains - 2025 earnings forecast lowered by 5.8% due to expected declines in asset management revenue and investment-related income [4][16] - **Revenue Breakdown**: AssetMark contributed approximately 45-50% of HTSC's asset management net revenue in 2023, generating Rmb3.79 billion in gross revenue and Rmb862.9 million in net profit [2][16] Market Conditions and Regulatory Environment - **Regulatory Normalization**: There are signs of regulatory normalization, but ongoing uncertainties remain regarding the earnings cycle and market conditions, particularly as A-share average daily trading (ADT) has dropped over 20% year-over-year in Q3 2024 [12][13] - **Future Deployment of Proceeds**: The proceeds from the AssetMark sale may be reserved for future capital needs, with potential deployment into cross-border equity and derivatives businesses, contingent on improved market conditions and regulatory environments [3][17] Valuation and Ratings - **Current Valuation**: HTSC's shares are considered fairly valued, with a price target of HK$9.60 for H-shares and Rmb13.10 for A-shares, implying a 14% upside for H-shares and 1% for A-shares [8][9] - **Rating**: Equal-weight (EW) rating for both H- and A-shares, reflecting cautious optimism due to expected ROE trends [15][18] Earnings Estimates and Ratios - **Earnings Estimates**: - 2024: Net profit expected to increase by 28.5% - 2025: Net profit expected to decrease by 5.8% - 2026: Estimates largely unchanged [4][6] - **Key Ratios**: - 2024 ROE projected at 8.2%, declining to 6.2% in 2025 due to the one-off gains from the AssetMark sale [15][24] Risks and Opportunities - **Upside Risks**: - Earlier-than-expected regulatory relaxation could enhance HTSC's capital deployment capabilities and improve profit margins [18] - Potential market share gains from competitors undergoing mergers [18] - **Downside Risks**: - Weaker equity market performance could negatively impact investment income and overall profitability [19] - Further declines in market ADT and margin finance volume could adversely affect brokerage and interest income [19] Conclusion - HTSC is navigating a challenging environment with significant changes due to the recent asset sale. While the immediate outlook for 2024 appears positive due to one-off gains, the company faces headwinds in 2025 and beyond, necessitating careful monitoring of market conditions and regulatory developments. The current valuation reflects a balanced view of these factors, with modest upside potential.

Company and Industry Summary Company Overview - The company reported a research and development expenditure of 49 million, which accounts for 1.9% of its revenue as of the reporting period [1] - As of the end of the reporting period, the company has obtained a total of 133 patents, including 40 new patents added during the reporting period [1] - The company has received recognition for three patents, which were awarded the PCQ International Invention Award [1]

Summary of the Conference Call Company and Industry - The conference call pertains to Kongcheng Pharmaceutical, focusing on its 2024 mid-year performance report Core Points and Arguments - The call began with a welcome message and a statement regarding the confidentiality of the content, indicating that it is intended solely for Xinyi Securities clients [1] Other Important but Possibly Overlooked Content - The audio and text records of the meeting are copyrighted by Xinyi Securities, and any reproduction without permission is considered an infringement [1]

Summary of the Conference Call Company and Industry - The conference call pertains to WeChat Group's mid-year corporate announcement for 2024 [1] Core Points and Arguments - The call is structured to allow investors to listen to the management's presentation, followed by a Q&A session [1] - The meeting is conducted in Mandarin with simultaneous translation available in English [1] - Participants can access the presentation slides on the online platform [1] Other Important Content - The call emphasizes the importance of investor engagement and transparency in corporate communications [1] - The company has made the decision to switch to a listen-only mode for the call, indicating a structured approach to information dissemination [1]

Key Points 1. Event Introduction - **Industry/Company**: Shensong International - **Event**: 2024 Q2 Earnings Release Conference Call - **Participants**: Investors, Management Team - **Moderator**: Jinmen Finance, Liu Teacher - **Time**: Evening - **Source**: <doc id='1'>1</doc> 2. Opening Remarks - **Industry/Company**: Shensong International - **Content**: Welcome message from the moderator, thanking participants for joining the conference call. - **Source**: <doc id='1'>1</doc>

哦哦 本次电话会议仅供符合国海证券投资者适当性管理要求的客户以及受邀客户使用国海证券不会因接收人收到本次会议相关通知或参加本次会议而释其为客户本次会议内容不构成任何投资建议据此作出的任何投资决策与国海证券国海证券员工或者关联机构无关本次会议只是转发国海证券已发布研究报告的部分观点仅反映国海证券研究人员于发布完整报告当日的判断 相关内容请以研究所已公开发布报告为准会议严禁录音或转发 任何人不得对本次会议的任何内容进行发布复制编辑改编转载播放展示或以其他任何方式非法使用本次会议的部分或者全部内容否则将承担相应的法律责任国海证券就此保留一切法律权利在任何情况下国海证券及其员工对使用本次会议信息或内容所引发的任何直接或间接损失概不负责市场有风险投资需谨慎 各位投资人大家晚上好我是国海传媒方如云然后今天来继续进行我们的泡玛特五节课的第二节课就是从渠道角度来穿透的来看泡玛特那今天正好就是在刚才呢泡泡也发布了今年上半年的整体的一个正式的预告那我可能先花一些时间来给大家大概分享一下今年上半年的业绩还有它整个上半年的一些亮点 首先是确实从业绩的角度它无论从收入还是利润都是同比非常高的增长并且是超过前段时间的预告的也是超大家的预 ...

本次电话会议仅供符合国海证券投资者适当性管理要求的客户以及受邀客户使用国海证券不会因接收人收到本次会议相关通知或参加本次会议而视其为客户本次会议内容不构成任何投资建议据此作出的任何投资决策与国海证券国海证券员工或者关联机构无关本次会议只是转发国海证券已发布研究报告的部分观点仅反映国海证券研究人员于发布完整报告当日的判断 相关内容请以研究所已公开发布报告为准会议严禁录音或转发 任何人不得对本次会议的任何内容进行发布复制编辑改编转载播放展示或以其他任何方式非法使用本次会议的部分或者全部内容否则将承担相应的法律责任国海证券就此保留一切法律权利在任何情况下国海证券及其员工对使用本次会议信息或内容所引发的任何直接或间接损失概不负责市场有风险投资需谨慎 各位投资人大家晚上好,我是国海商社的熊思宇。今天给大家汇报的主题主要是达市股份这个个股的深度汇报。那我们近期也是看到了达市股份,它被调整进入最新的恒生指数的成分股。 那可能他入通的这样的预期可能会相对更明确一些。那我们也是正在现在这个时点去做一下这个公司的一个基本面情况,以及他投资逻辑的这样的一个深度汇报。 首先其实达市股份它是达美乐品牌在中国国内唯一的一家特许经营商我们 ...

感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议 大家好欢迎参加远大一二二零二四年中企业企业交流会目前所有参会者均处于静音状态下面开始公报声明本次会议仅服务邀请参会的广大投资者会以PPT音频及文字记录的内容仅供参会者内部使用不得公开发布 远大医药为授权人和媒体转发本次会议相关内容未经允许和授权的转载转发均属侵权远大医药将保留追究其法律责任的权利远大医药不承担因转载转发而产生的任何损失和责任市场有风险投资需谨慎提醒广大投资者谨慎做出投资决策在会议开始前我们提示各位投资者在主讲嘉宾翻译结束后将留有提问时间接下来有请公司主持人发言谢谢 各位投资人大家上午好非常感谢大家来参加中金公司中进证券华泰证券新业证券国进证券国源证券医药团队联合举办的远大医药2024年中期业绩交流会我本人是中金医药分析师朱元音在线的还有我的同事刘亚军博士 那今天呢我们先非常荣幸邀请到公司的各位管理层他们分别是广社会主席总裁唐伟坤博士行政总裁周超先生财务及运营副总裁姚薇女士来参加本次业绩电话会那么公司昨天也公布了202 ...

周一早上九点加入我们的奈叙特解读电话会我们也是看到了奈叙特上周发布了中报今天我们也是非常高兴的请到了奈叙特的IR总监Tony王王宇同王总跟大家来一块解读王总您好你好 非常感谢接触相信大家也是对奈斯特比较熟悉了那么我们今天也就是简要的我这边来播报一下中报的情况然后后面就直接进入到问答的环节 那么我们看到公司上半年的这个营收情况上半年是营收21亿美元同比基本上持平这个规模净利润是大约在1600万美元同比有一定的 这个下降这个扣分也是跟这个规模的同比下降幅度差不多都是50%左右但是公司上半年毛利率在这个10.5个点比2023年上半年和2023年全年都有一个点左右的这个回升那么一币大率是这个也是有一定的这个回升那么我们也是看到了公司上周发布的中报然后这边的话 我也是收集了比较多的投资者的提问,我们可能就先逐一的向王总请教,然后后面如果有时间的话,我们来进行自由的提问。首先就是想请教一下,我们上半年其实毛利率和EBITDA占营收的比例, 同比去年同期都是有提升的但是我们看到净利润是有不小幅度的下滑您是否能解读一下这里面的一些差异然后导致利润下滑的在盲利率和ebitda以外的重点因素是什么谢谢好的谢谢一鸣谢谢大家早上的时 ...